Trials / Completed
CompletedNCT02634801
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fumaric Acid Esters | Administered orally |
| DRUG | Methotrexate | Administered orally |
| DRUG | Ixekizumab | Administered SC |
Timeline
- Start date
- 2016-01-20
- Primary completion
- 2016-11-29
- Completion
- 2017-11-14
- First posted
- 2015-12-18
- Last updated
- 2019-10-09
- Results posted
- 2018-07-18
Locations
21 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02634801. Inclusion in this directory is not an endorsement.